Cost of revenue · 2016–2025
Supernus Pharmaceuticals cost of revenue
$74.6M−4.3% · FY2025
Supernus Pharmaceuticals (SUPN) reported $74.6M in cost of revenue for fiscal 2025, −4.3% year on year.
| Fiscal year | Cost of revenue | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $74.6M | −4.3% | Open → |
| FY20242024-12-31 | $77.9M | −7.0% | Open → |
| FY20232023-12-31 | $83.8M | −3.9% | Open → |
| FY20222022-12-31 | $87.2M | +66.3% | Open → |
| FY20202020-12-31 | $52.5M | +214.9% | Open → |
| FY20192019-12-31 | $16.7M | +8.5% | Open → |
| FY20182018-12-31 | $15.4M | +0.9% | Open → |
| FY20172017-12-31 | $15.2M | +26.9% | Open → |
| FY20162016-12-31 | $12.0M | — | Open → |
Cost of revenue — Cost of revenue is the direct cost of producing what the company sold — materials, manufacturing and the labour tied to delivery. It excludes sales, marketing and administration. Revenue minus this figure is gross profit.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2016–2025 compound annual growth +22.5%
Cost of revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Supernus Pharmaceuticals cost of revenue |url=https://companiesranked.com/en/company/supernus-pharmaceuticals/cost-of-revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Supernus Pharmaceuticals cost of revenue. CompaniesRanked. https://companiesranked.com/en/company/supernus-pharmaceuticals/cost-of-revenueBibTeX
@misc{companiesranked-en-company-supernus-pharmaceuticals-cost-of-revenue-2026,
author = {{CompaniesRanked}},
title = {{Supernus Pharmaceuticals cost of revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/supernus-pharmaceuticals/cost-of-revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001356576-26-000011 · March 2, 2026
{{cite web |title=Supernus Pharmaceuticals cost of revenue — 10-K (0001356576-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.